Next Article in Journal
Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition
Next Article in Special Issue
Leptin Receptor Gene Variant rs11804091 Is Associated with BMI and Insulin Resistance in Spanish Female Obese Children: A Case-Control Study
Previous Article in Journal
Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases
Previous Article in Special Issue
Obesity and Asthma: A Missing Link
Open AccessReview

Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions

Department of Internal Medicine I, Gastroenterology, Hepatology & Endocrinology, Medical University Innsbruck, A-6020 Innsbruck, Austria
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(8), 1649; https://doi.org/10.3390/ijms18081649
Received: 18 July 2017 / Revised: 18 July 2017 / Accepted: 26 July 2017 / Published: 29 July 2017
(This article belongs to the Special Issue Adipokines)
Accumulating evidence links obesity with low-grade inflammation which may originate from adipose tissue that secretes a plethora of pro- and anti-inflammatory cytokines termed adipokines. Adiponectin and leptin have evolved as crucial signals in many obesity-related pathologies including non-alcoholic fatty liver disease (NAFLD). Whereas adiponectin deficiency might be critically involved in the pro-inflammatory state associated with obesity and related disorders, overproduction of leptin, a rather pro-inflammatory mediator, is considered of equal relevance. An imbalanced adipokine profile in obesity consecutively contributes to metabolic inflammation in NAFLD, which is associated with a substantial risk for developing hepatocellular carcinoma (HCC) also in the non-cirrhotic stage of disease. Both adiponectin and leptin have been related to liver tumorigenesis especially in preclinical models. This review covers recent advances in our understanding of some adipokines in NAFLD and associated HCC. View Full-Text
Keywords: Adipokines; hepatocellular cancer; metabolism; metabolic inflammation; non-alcoholic fatty liver disease (NAFLD) Adipokines; hepatocellular cancer; metabolism; metabolic inflammation; non-alcoholic fatty liver disease (NAFLD)
Show Figures

Graphical abstract

MDPI and ACS Style

Adolph, T.E.; Grander, C.; Grabherr, F.; Tilg, H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. Int. J. Mol. Sci. 2017, 18, 1649. https://doi.org/10.3390/ijms18081649

AMA Style

Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. International Journal of Molecular Sciences. 2017; 18(8):1649. https://doi.org/10.3390/ijms18081649

Chicago/Turabian Style

Adolph, Timon E.; Grander, Christoph; Grabherr, Felix; Tilg, Herbert. 2017. "Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions" Int. J. Mol. Sci. 18, no. 8: 1649. https://doi.org/10.3390/ijms18081649

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop